

### **RESEARCH PAPER**

# Patient Outcomes and Factors Associated with Healing in Calciphylaxis Patients Undergoing Adjunctive Hyperbaric Oxygen Therapy



## Norman McCulloch, MD<sup>a</sup>, Susan M. Wojcik, PhD<sup>b</sup>, Marvin Heyboer III, MD<sup>c,\*</sup>

<sup>a</sup>Fellowship in Undersea & Hyperbaric Medicine, Department of Emergency Medicine, Division of Hyperbaric Medicine and Wound Care, SUNY Upstate Medical University, Syracuse, NY, USA <sup>b</sup>Department of Emergency Medicine, SUNY Upstate Medical University, Syracuse, NY, USA; and <sup>c</sup>Department of Emergency Medicine, Division of Hyperbaric Medicine and Wound Care, SUNY Upstate Medical University, 550 East Genesee Street, Suite 103, Syracuse, NY 13202, USA

#### **KEYWORDS:**

Calciphylaxis; Hyperbaric; Oxygen Abstract Calcific uremic arteriolopathy, also known as calciphylaxis, is a rare syndrome of small vessel calcification of unknown etiology causing painful, violaceous skin lesions that progress to form chronic non-healing ulcers and gangrene. Hyperbaric oxygen therapy (HBOT) can be used as adjunctive therapy in the treatment of these ulcers. However, due to paucity of cases, there is limited data on the clinical benefit of HBOT and identifying factors associated with healing. The purpose of this study was to determine patient outcomes and factors associated with healing in patients with calciphylaxis undergoing HBOT. A retrospective chart review was completed on patients who were diagnosed with calciphylaxis and had hyperbaric medicine consultation between May 2012 and January 2016. Clinical outcomes, demographics, risk factors, laboratory values, wound distribution, and HBOT profiles were collected and analyzed. We identified 8 patients. Out of 8 patients consulted for calciphylaxis, five were consented and underwent HBOT (2 males and 3 females). All had coexisting ESRD and Diabetes. All males were able to tolerate being in the chamber and received therapeutic treatments (at least 20 HBOT) with complete resolution of ulcers. HBOT was discontinued in one female due to an inconsistent biopsy report and two others due to death secondary to septic shock or respiratory arrest and severe uremia. Calciphylaxis is a devastating disease with a high mortality rate. Our results demonstrated a positive response to HBOT especially when receiving at least 20 treatments. A majority of calciphylaxis cases are females and indeed female gender has been cited as a risk factor for this disease. However, current literature has not conferred a relationship between gender nor the number of HBOT received and outcomes. Our results showed that males had a more favorable outcome provided they received at least twenty HBOT. Further prospective studies are needed to elucidate these outcomes.

© 2016 Elsevier Inc. All rights reserved.

The information has not been previously reported.

Disclaimers: None. The authors have no conflict-of-interest and no financial disclosures to make.

\* Corresponding author. Fax: +1 315 464 4854. E-mail address: heyboerm@upstate.edu

#### Introduction

Calciphylaxis (also known as calcific uremic arteriolopathy) is a rare and potentially life threatening syndrome of small vessel calcification of unknown etiology,

2213-5103/\$ - see front matter © 2016 Elsevier Inc. All rights reserved. http://dx.doi.org/10.1016/j.jccw.2016.08.004 which causes painful violaceous skin lesions that progress to chronic, non-healing ulcers and subsequent gangrene. It is commonly seen in end-stage renal disease (ESRD) patients with a prevalence of 1-4% of those on hemodialysis.<sup>1,2</sup> Incidence has been reported to be increasing recently.<sup>3</sup> With a high mortality between 60 and 80%, most patients die from complications of sepsis secondary to infection of the calciphylaxis wounds, which results from impaired integrity of the epidermis and dermis.<sup>4</sup> The exact pathogenesis is unclear but involves vascular calcification with calcium deposition in the media of the dermal and subcutaneous arterioles and cutaneous necrosis.<sup>5</sup> Although various sites have been reported, the lower extremities are the most commonly involved.<sup>5</sup>

Hyperbaric oxygen (HBO<sub>2</sub>) is a treatment in which the patient breathes 100% oxygen at a pressure higher than ambient sea-level pressure (1 atmosphere absolute -ATA) while inside a sealed chamber. It has been proven successful as adjunctive treatment of problem wounds, defined as those that fail to respond to standard medical and surgical management. These wounds are often severely hypoxic with transcutaneous oxygen pressures  $(P_{tc}O_2)$  of less than 40 mmHg. Normal tissue has  $P_{tc}O_2$ of greater than 50 mmHg.<sup>6</sup> Impaired healing is noted when tissue O<sub>2</sub> tension is less than 40 mmHg. HBOT improves the oxygen tension and promotes wound healing effects including through increased fibroblast proliferation, collagen production and neogenesis. HBOT also reverses the local tissue hypoxia that inhibits the oxygen-dependent polymorphonuclear leukocytemediated bacterial killing of organisms that are most commonly found in wound infections.<sup>7</sup>

The benefits of HBO<sub>2</sub> in the treatment of calciphylaxis have been reported in many case reports and a few retro-spective case series.<sup>2,8–10</sup> In Podymow et al 2 out of 5 patients showed complete resolution of extensive necrotic ulcers and improvement in wound area transcutaneous oxygen pressure.<sup>2</sup> Dean and Werman report a case of a female patient with end-stage renal disease and diabetes mellitus who presented with lower extremity calciphylaxis who responded to 7 weeks of HBO<sub>2</sub> treatments after failing to respond to standard care including parathyroidectomy and wound debridement.9 Vassa et al reported on a case of a woman on continuous ambulatory peritoneal dialysis who presented with lower extremity calciphylaxis who also failed standard care but showed resolution of her skin lesions after 38 HBO<sub>2</sub> therapy sessions.<sup>8</sup> The majority of calciphylaxis patients are females. However, gender has not been reported to confer an advantage (or disadvantage) in treatment. We thus present a retrospective study of eight patients on renal replacement therapy who underwent consultation for calciphylaxis and their outcomes.

#### Methods

We obtained IRB exemption for our retrospective case review. We identified patients admitted to Upstate Medical University who received hyperbaric medicine consultation for lesions suspicious for calciphylaxis from May 2012 through Jan 2016. Eight cases were retrospectively studied. Characteristics of each patient including age, gender, dialysis, duration on dialysis, presence of diabetes mellitus, evidence of parathyroidectomy, use of sodium thiosulfate, use of coumadin, distribution of calciphylaxis lesions, serum levels of calcium, phosphate, albumin, hyperbaric oxygen treatment profile, and clinical outcomes were recorded. Patients, who underwent treatment received hyperbaric oxygen at 2.0 atmospheres absolute (ATA) for 90 min, 5 days per week for variable number of treatments. All patients received routine wound care, and the majority of patients who underwent hyperbaric oxygen therapy were also treated with sodium thiosulfate concurrently. Presence of increased granulation tissue, overall reduction in ulcer size dimensions with subsequent epithelialization and formation of scar determined resolution of calciphylaxis lesions.

#### Results

Patient characteristics are illustrated in Table 1. Six females and two males were identified. Mean age of females was 52.2 years and males 62.5 years. Five patients (4 females, 1 male) had biopsy confirmed calciphylaxis. All were diagnosed with end-stage renal disease on renal replacement therapy and diabetes mellitus. Average duration on dialysis was 34 months. Five patients were receiving anticoagulation with warfarin for atrial fibrillation, and this was discontinued when clinically appropriate. Out of the eight patients identified, seven received supplemental vitamin D and calcium acetate as part of their treatment for secondary hyperparathyroidisim and three underwent parathyroidectomy for refractory secondary hyperparathyroidism. Calciphylaxis lesions were located on the lower extremities in six patients, on the trunk in one and in the lungs in one patient.

Table 2 summarizes the laboratory findings. Average serum PTH level was 693.7 pg/ml, calcium 5.3 mg/dl and phosphate 8.4 mg/dl. Elevated calcium-phosphate product was not identified in any of the patients. Mean serum albumin was 3.3 mg/dl with three patients demonstrating hypoalbuminemia (serum albumin < 3.5 mg/dl).

Table 3 identifies the clinical course of patients. Five patients underwent  $HBO_2$  therapy of which two (both males) received therapeutic treatments (at least 20  $HBO_2$  treatments). Patients #1 and #5 showed excellent clinical response with resolution of skin ulcers. Healing occurred

Table 1 Patient characteristics.												
Patient	Age (yrs)	Sex	Diabetes Mellitus	Renal Replacement	Duration on Dialysis (Months)	Parathyroidectomy	Biopsy	STS	Warfarin	Calcium	Vitamin D	Wound Distribution
1	62	М	Yes	Yes		Yes	Yes	Yes	No	Yes	Yes	Lower extremity
2	55	F	Yes	Yes	5	No	Yes	Yes	No	Yes	Yes	Lungs
3	51	F	Yes	Yes	36	No	No	Yes	No	Yes	Yes	Trunk/lower extremity
4	55	F	Yes	Yes		Yes	Yes	Yes	Yes	Yes	Yes	Lower extremity
5	63	М	Yes	Yes	24	No	No	Yes	Yes	No	Yes	Lower extremity
6	47	F	Yes	Yes		No	Yes	No	Yes	Yes	Yes	Lower extremity
7	62	F	Yes	Yes	84	Yes	Yes	Yes	Yes	Yes	Yes	Lower extremity
8	43	F	Yes	Yes	21	No	No	Yes	Yes	Yes	Yes	Lower extremity

during the course of treatments for patient #1 (Figs. 1 and 2) and after completion for patient #5. In the remaining three patients who underwent HBO<sub>2</sub> therapy, all of which were females, treatment was suspended early. Patient #3 biopsy results were found not to be consistent with calciphylaxis. In patients #4 and #8, both requested to withdraw treatment early due to severe intractable pain and the inability to tolerate supine position while in the chamber. Both of these patients developed other medical complications (septic shock and respiratory arrest due to uremia respectively) and died. Patient #6 was made palliative care and patient #7 exhibited severe confinement anxiety. In patient #2 lesions were identified in the lungs (pulmonary calciphylaxis) and thus no treatment was administered.

#### Discussion

This retrospective study included eight patients who were admitted to our hospital with lesions suspicious for calciphylaxis. Five patients underwent biopsies of which four patients had biopsy-confirmed calciphylaxis. All patients who were treated with HBO<sub>2</sub> received concurrent sodium thiosulfate. In one patient (#3) the lesions were located in her lungs. HBO<sub>2</sub> was initially started and subsequently discontinued as the biopsy results were not

Table 2	Laboratory values.						
Patient	PTH (pg/ml)	PO <sub>4</sub> (mg/dl)	Calcium (mg/dl)	Albumin (mg/dl)			
	(P3/)	(	(	(			
1		9.0	6.8				
2	217	7.5	4.3	2.8			
3	836	8.8	5.5	3.0			
4	1398	8.2	5.6	3.6			
5		8.8	6.5				
6	737	7.7	4.2	2.7			
7	664	8.8	4.1	3.9			
8	310	8.4	5.4	3.7			
-							

consistent calciphylaxis. Two patients showed clinical improvement in their lesions with complete resolution of lesions seen in one patient based on wound area measurements (Table 1). Both of these patients (#1 and #5) were able to tolerate being in a monoplace chamber environment and received at least twenty HBO<sub>2</sub> treatments (which was considered therapeutic cut-off). In contrast, the other four patients received less than twenty treatments and did not demonstrate any clinical improvement in their lesions. Of the four patients (#3, #4, #7, #8) who received HBO<sub>2</sub> but did not improve all were females and morbidly obese based off body-mass index measurements.

Both female gender and obesity have been reported as risk factors for the development of calciphylaxis.<sup>10</sup> However, neither gender nor the number of treatments received have been reported as prognostic factors in overall healing.

Table 3	Patient outcomes.					
Patient	Number of HBO <sub>2</sub> Treatments	Outcome				
1	28	Complete resolution of lower extremity lesions				
2	0	Patient lost to follow up				
3	10	Treatment aborted as wound biopsy results not consistent with calciphylaxis				
4	14	Patient died secondary to septic shock				
5	60	Lower extremity ulcers clinically improved; partial resolution				
6	0	Palliative care was instituted				
7	1	Unable to tolerate treatment due to severe confinement anxiety. Patient eventually died				
8	12	Requested withdrawal of care. Palliative care started. Patient died secondary to respiratory arrest				

\_ ..



**Figure 1** Patient #1, calciphylaxis lesions of right (a) and left (b) lower extremities lesions.

In our study, six patients were female and 2 were male. The two patients who showed clinical benefit from HBO<sub>2</sub> were both males and received greater than twenty HBO<sub>2</sub> treatments. The majority of the case series reported demonstrate a female preponderance. In two of the largest case series reported, Podymow et al had four out of five patients who were female and Basile et al had six out of eleven patients who were female.<sup>10,11</sup> In both of these studies, all patients received at least twenty HBO<sub>2</sub> treatments. In our study, the majority of the patients were females and this is consistent with what has been reported in the literature. Our male patients appeared to be able to tolerate treatments more favorably resulting in clinical benefit.

It is important to note that all patients received concurrent HBO<sub>2</sub> and sodium thiosulfate. Adjunctive HBO<sub>2</sub> has been reported as having a beneficial direct effect in calciphylaxis by aiding in wound healing and reducing mortality.<sup>12,13</sup> Case reports demonstrating clinical improvement of calciphylaxis have employed both of these treatment modalities with success.<sup>8,9,11</sup> Chronic, non-healing wounds such as calciphylaxis, are often hypoxic with tissue partial



**Figure 2** Patient #1 showing complete resolution of lower extremity right (a) and left (b).

pressures of oxygen (pO<sub>2</sub>) less than 40 mmHg. Tissue hypoxia contributes to poor wound healing as the formation of collagen matrix and angiogenesis are directly related to adequate oxygen tension.<sup>14</sup> Hyperbaric oxygen therapy involves breathing 100% oxygen at a pressure of 2–3 times atmospheric pressure with many demonstrable effects in wound healing including reversal of wound hypoxia, upwards to level of at least 400 mmHg.<sup>15</sup> In addition to counteracting local wound hypoxia, hyperbaric oxygen also promotes vasoconstriction resulting in decreased edema, inhibits neutrophil adhesion and subsequent inflammatory cascade, increases neutrophil bactericidal activity and augments the bacteriostatic or bactericidal effects of certain antibiotics against anaerobic micro-organisms resulting in better control of wound infections.

In conclusion, two of six patients in our retrospective study demonstrated clinical improvement in their calciphylaxis lesions when treated with HBO<sub>2</sub> and concurrent sodium thiosulfate therapy. Although there are no reports of gender or number of hyperbaric oxygen treatments administered as prognostic factors, our study demonstrated males tolerated treatment better and were able to receive at least twenty hyperbaric oxygen treatments resulting in clinical improvement. Further prospective studies are needed to identify whether certain patient characteristics as well as number of hyperbaric oxygen treatments administered play a role in healing in calciphylaxis patients.

#### References

- Angelis M, Won LL, Myers SA, Wong LM: Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery. 1997;122:1083–1090.
- Podymow T, Wherrett C, Burns KD: Hyperbaric oxygen in the treatment of calciphylaxis: a case series. Nephrol Dial Transplant. 2001;16: 2176–2180.
- Coates T, Kirkland G, Dymock R, et al: Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis. 1998;32:384–391.
- Budisavljevic MN, Cheek D, Ploth DW: Calciphylaxis in chronic renal failure. J Am Soc Nephrol. 1996;7:978–982.
- Bhambri S, Bhambri A, Del Rosso J: Calciphylaxis: a review. J Clin Aesthetic Dermatol. 2008;1(20):38–41.
- Sheffield PJ: Measuring tissue oxygen tension: a review. Undersea Hyperb Med. 1998;25:179–188.

- Hampson NB: Hyperbaric Oxygen Therapy: 1999 Committee Report. Kensington: MD Undersea and Hyperbaric Medical Society; 1999. p. 27–34.
- Vassa N, Twardowski ZJ, Campbell J: Hyperbaric oxygen therapy in calciphylaxis-induced skin necrosis in a peritoneal dialysis patient. Am J Kidney Dis. 1994;23:878–881.
- Dean SM, Werman H: Calciphylaxis: a favorable outcome with hyperbaric oxygen. J Vasc Med. 1998;3:115–120.
- Rogers NM, Teubner DJO, Coates PTH: Calcific uremic arteriolopathy: advances in pathogenesis and treatment. Semin Dial. 2007;20: 150–157.
- Basile C, Montanaro A, Masi M, et al: Hyperbaric oxygen therapy for calcific uremic arteriolopathy: a case series. J Nephrol. 2002;15(6): 676–680.
- Rogers N, Chang S, Teubner D, Coates P: Hyperbaric oxygen as effective adjuvant therapy in the treatment of distal calcific uraemic arteriolopathy. Nephrol Dial Transplant Plus. 2008;1:244–249.
- Rogers NM, Coates PTH: Calcific uremic arteriolopathy: an update. Curr Opin Nephrol Hypertens. 2008;17:629–634.
- Davis JC, Hunt TK, editors. Problem Wounds The Role of Oxygen. New York: Elsevier Science, 1998.
- Don BR, Chin AI: A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies. Clin Nephrol. 2003;59:463–470.